Results 201 to 210 of about 71,240 (317)

Temporal Association Between COVID‐19 Vaccination and HBsAg Loss in Chronic Hepatitis B Infection: An Interrupted Time Series Analysis

Alimentary Pharmacology &Therapeutics, EarlyView.
In 59,946 chronic hepatitis B patients followed over 23 years, COVID‐19 vaccination rollout was temporally associated with a 56% increase in HBsAg loss rates (peak 1.27 per 100 person‐years in 2022), followed by gradual waning. Negative control outcomes showed no similar pattern, supporting biological specificity. ABSTRACT Background and Aims Hepatitis
Jonggi Choi, Allison Carroll, Vy H. Nguyen, Megan Michta, Xuan Q. Zhang, Young‐Suk Lim, Raymond T. Chung   +6 more
wiley   +1 more source

Bivalent virus-like particles expressing SPECT1 and CSP trigger pre-erythrocytic malaria immunity and protect against transgenic <i>Plasmodium falciparum</i> sporozoite challenge in mice. [PDF]

Front Immunol
Turan G, Mukhopadhyay E, Truby A, Fedorova K, Peralta Alvarez MP, Alharbi NK, Hill AVS, Salman AM.   +7 more
europepmc   +1 more source

Incidence of Hepatitis B Virus Reactivation in Patients Treated With Immunosuppressive and Chemotherapeutic Agents

Alimentary Pharmacology &Therapeutics, EarlyView.
HBV reactivation incidence varied across immunosuppressive and chemotherapeutic agents. Clinically meaningful HBV reactivation was also observed in patients receiving corticosteroids and conventional immunosuppressive therapies. ABSTRACT Background Data on the incidence of hepatitis B virus reactivation (HBVr) remain limited. In Japan, patients who are
Kazuhiko Ikeuchi, Makoto Saito, Kazuya Okushin, Toshiyuki Kishida, Akira Kado, Kyoji Moriya, Kazuhiko Koike, Takeya Tsutsumi, Hiroshi Yotsuyanagi   +8 more
wiley   +1 more source

Dendritic Cell Served as Salvage Therapy for Advanced Hepatocellular Carcinoma Resistant to Tyrosine Kinase or Immune Checkpoint Inhibitors. [PDF]

Cancers (Basel)
Lee WC, Wu TH, Cheng CH, Lai Y, Hung HC, Lee JC, Wang YC, Lee CF, Wu TJ, Chou HS, Chan KM.   +10 more
europepmc   +1 more source

Sustained HBsAg clearance induced by pegylated interferon α-2b in HBeAg-negative patients with low baseline HBsAg. [PDF]

Front Cell Infect Microbiol
Wen C, He T, Zha G, Li A, Wang Z, Zhou Z, Cai D, Zhang D, Peng M, Shi X, Ren H.   +10 more
europepmc   +1 more source

Marked variation in eligibility criteria across registrational trials for relapsed diffuse large B‐cell lymphoma limits applicability to clinical practice

British Journal of Haematology, EarlyView.
Summary Therapeutic options for relapsed or refractory diffuse large B‐cell lymphoma (rDLBCL) have expanded following accelerated approvals based largely on surrogate end‐points, yet confirmatory studies have not consistently reproduced these benefits across all agents, and outcomes for many patients remain poor.
Elizabeth Goodall, Jodie Palmer, Arina Martynchyk, Niamh Waters, Fiona Swain, Tran Binh Giang, Tamara Marconi, Jamie Brennan, Gareth P. Gregory, Chan Cheah, Colm Keane, Eliza A. Hawkes   +11 more
wiley   +1 more source

MAGa: Monoclonal Autoimmune Gammopathies. [PDF]

Cancers (Basel)
Torres S, Wheeler SE, Shurin MR.
europepmc   +1 more source

Phenotype‐specific immune profiles and outcomes in childhood autoimmune neutropenia: A 20‐year cohort study

British Journal of Haematology, EarlyView.
Summary Childhood autoimmune neutropenia (AIN) encompasses heterogeneous entities; phenotype‐specific immunological profiles and their relationship to infection outcomes remain incompletely defined. To characterise clinical, immunological and long‐term outcomes across distinct phenotypes of childhood AIN.
Ioanna Saougou, Chrysoula Kosmeri, Nikolaos Chaliasos, Irene Mavroudi, Charalampos Pontikoglou, Alexandros Makis   +5 more
wiley   +1 more source

Lipid Nanoparticle-Encapsulated PolyI:C as an Adjuvant Enhances Both Humoral and Cellular Immune Responses to the Hepatitis B Vaccine. [PDF]

Vaccines (Basel)
Zhao Z, Wang B, Wang H, Zhang Q, Liang Y, Liu Y.   +5 more
europepmc   +1 more source

Hepatitis B-Virus-e-Antigen [PDF]

, 2019
openaire   +1 more source